Details of the Drug

General Information of Drug (ID: DMUBYFM)

Drug Name

ACE-041

Synonyms

N-(5-bromo-2-methylpyridin-4-yl)acetamide; 1244949-22-1; ACE041; DTXSID10670359; 4605AA; ZINC38540942; AKOS016011880; FCH1349294; AJ-96556; EN001564; KB-258244; AX8247344; Acetamide, N-(5-bromo-2-methyl-4-pyridinyl)-

Indication

Disease Entry	ICD 11	Status	REF
Age-related macular degeneration	9B75.0	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

229.07

Logarithm of the Partition Coefficient (xlogp)

1.1

Rotatable Bond Count (rotbonds)

1

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

2

Chemical Identifiers

Formula: C8H9BrN2O
IUPAC Name: N-(5-bromo-2-methylpyridin-4-yl)acetamide
Canonical SMILES: CC1=CC(=C(C=N1)Br)NC(=O)C
InChI: InChI=1S/C8H9BrN2O/c1-5-3-8(11-6(2)12)7(9)4-10-5/h3-4H,1-2H3,(H,10,11,12)
InChIKey: OMGSODSTISOTIL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 45480413
CAS Number: 1244949-22-1
TTD ID: D0N9PL

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 2 (GDF2)	TTAP4T1	GDF2_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
2	Company report (Acceleron Pharma)